Clinical Trial Update: CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension [Phase 2]

View source ↗

Summary

Phase 2 trial comparing CD101 to caspofungin followed by oral step-down in candidemia and invasive candidiasis completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidemia
• Fungal Infections
• Invasive Candidiasis

Drugs mentioned

• CD101
• Caspofungin (caspofungin)

Snippet

Sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Candidemia, Mycoses | Phase 2 | Status: COMPLETED | Results posted: 2020-12-08